Macitentan 10 mg: Clinical Trials

11 trials of Macitentan 10 mg, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 4 terminated, 1 active not recruiting. 7 Phase 3, 3 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	7	Completed 3, Terminated 3, Active not recruiting 1
Phase 1	3	Completed 3
Phase 2	1	Terminated 1

Follow Macitentan 10 mg: new trials by email Literature Review of Macitentan 10 mg trials Research Report on Macitentan 10 mg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC - Healthy	Phase 1	Completed	Actelion	40	2022-02-04	2025-03-30
A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil FDC of macitentan/tadalafil (10 mg/20 mg), Macitentan 10 mg, Tadalafil 20 mg - Healthy	Phase 1	Completed	Janssen Research & Development, LLC	18	2021-04-30	2025-03-30
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg - Pulmonary Arterial Hypertension	Phase 3	Active not recruiting	Actelion	935	2020-06-30	2026-10-06
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg - Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)	Phase 3	Completed	Actelion	187	2019-07-29	2025-12-19
An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients. macitentan 10 mg - Congenital Heart Disease With Fontan Circulation	Phase 3	Terminated	Actelion	112	2019-04-11	2023-03-07
A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH). macitentan 10 mg - Chronic Thromboembolic Pulmonary Hypertension (CTEPH)	Phase 3	Terminated	Actelion	9	2019-01-08	2021-06-18
A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease macitentan 10 mg - Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease	Phase 2	Terminated	Actelion	91	2018-12-07	2025-02-04
Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects Macitentan 10 mg, Placebo - Congenital Heart Disease	Phase 3	Completed	Actelion	142	2017-08-14	2025-03-30
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome Macitentan 10 mg, Placebo - Pulmonary Arterial Hypertension	Phase 3	Completed	Actelion	226	2013-05-21	2018-02-23
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients Macitentan 3 mg, Macitentan 10 mg, Placebo - Digital Ulcers	Phase 3	Terminated	Actelion	265	2011-12-01	2025-02-04
Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects Moxifloxacin 400 mg, Macitentan 10 mg, Macitentan 30 mg - Healthy	Phase 1	Completed	Actelion	64	2011-08-01	2025-02-03

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding